Cargando…

Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro

BACKGROUND AND AIMS: Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordi, Licia, Lalle, Eleonora, Caglioti, Claudia, Travaglini, Damiano, Lapa, Daniele, Marsella, Patrizia, Quartu, Serena, Kis, Zoltan, Arien, Kevin K., Huemer, Hartwig P., Meschi, Silvia, Ippolito, Giuseppe, Di Caro, Antonino, Capobianchi, Maria R., Castilletti, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333211/
https://www.ncbi.nlm.nih.gov/pubmed/25693189
http://dx.doi.org/10.1371/journal.pone.0116816
_version_ 1782357995475173376
author Bordi, Licia
Lalle, Eleonora
Caglioti, Claudia
Travaglini, Damiano
Lapa, Daniele
Marsella, Patrizia
Quartu, Serena
Kis, Zoltan
Arien, Kevin K.
Huemer, Hartwig P.
Meschi, Silvia
Ippolito, Giuseppe
Di Caro, Antonino
Capobianchi, Maria R.
Castilletti, Concetta
author_facet Bordi, Licia
Lalle, Eleonora
Caglioti, Claudia
Travaglini, Damiano
Lapa, Daniele
Marsella, Patrizia
Quartu, Serena
Kis, Zoltan
Arien, Kevin K.
Huemer, Hartwig P.
Meschi, Silvia
Ippolito, Giuseppe
Di Caro, Antonino
Capobianchi, Maria R.
Castilletti, Concetta
author_sort Bordi, Licia
collection PubMed
description BACKGROUND AND AIMS: Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while established CCHFV infection is almost insensitive to subsequent IFN-α treatment. No data concerning type III IFNs antiviral activity against CCHFV are available so far. The aim of the present study was to explore the capability of IFN-λ1 to inhibit the replication of CCHFV and the possible synergism/antagonism between IFN-α and IFN-λ1 both in the inhibition of CCHFV replication and in the activation of intracellular pathways of IFN response. METHODS: Human A549 and HuH7 cells were treated with increasing amounts of IFN-λ1, or IFN-α or a combination of them, infected with CCHF; the extent of virus yield inhibition and the induction of MxA and 2’-5’OAS mRNA was measured. RESULTS AND CONCLUSIONS: Our study pointed out that type III IFN possess an antiviral activity against CCHFV, even if lower than type I IFN. Moreover, a clear antagonism between IFN-λ and IFN–α was observed in both cell lines (A549 and HuH7 cells), in terms of antiviral effect and activation of pivotal ISGs, i.e. MxA and 2’-5’OAS. Elucidating the interplay between type I and III IFNs will help to better understand innate defence mechanisms against viral infections and may provide novel scientific evidence for a more rational planning of available and future treatments, particularly against human diseases caused by high concern viruses.
format Online
Article
Text
id pubmed-4333211
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43332112015-02-24 Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro Bordi, Licia Lalle, Eleonora Caglioti, Claudia Travaglini, Damiano Lapa, Daniele Marsella, Patrizia Quartu, Serena Kis, Zoltan Arien, Kevin K. Huemer, Hartwig P. Meschi, Silvia Ippolito, Giuseppe Di Caro, Antonino Capobianchi, Maria R. Castilletti, Concetta PLoS One Research Article BACKGROUND AND AIMS: Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while established CCHFV infection is almost insensitive to subsequent IFN-α treatment. No data concerning type III IFNs antiviral activity against CCHFV are available so far. The aim of the present study was to explore the capability of IFN-λ1 to inhibit the replication of CCHFV and the possible synergism/antagonism between IFN-α and IFN-λ1 both in the inhibition of CCHFV replication and in the activation of intracellular pathways of IFN response. METHODS: Human A549 and HuH7 cells were treated with increasing amounts of IFN-λ1, or IFN-α or a combination of them, infected with CCHF; the extent of virus yield inhibition and the induction of MxA and 2’-5’OAS mRNA was measured. RESULTS AND CONCLUSIONS: Our study pointed out that type III IFN possess an antiviral activity against CCHFV, even if lower than type I IFN. Moreover, a clear antagonism between IFN-λ and IFN–α was observed in both cell lines (A549 and HuH7 cells), in terms of antiviral effect and activation of pivotal ISGs, i.e. MxA and 2’-5’OAS. Elucidating the interplay between type I and III IFNs will help to better understand innate defence mechanisms against viral infections and may provide novel scientific evidence for a more rational planning of available and future treatments, particularly against human diseases caused by high concern viruses. Public Library of Science 2015-02-18 /pmc/articles/PMC4333211/ /pubmed/25693189 http://dx.doi.org/10.1371/journal.pone.0116816 Text en © 2015 Bordi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bordi, Licia
Lalle, Eleonora
Caglioti, Claudia
Travaglini, Damiano
Lapa, Daniele
Marsella, Patrizia
Quartu, Serena
Kis, Zoltan
Arien, Kevin K.
Huemer, Hartwig P.
Meschi, Silvia
Ippolito, Giuseppe
Di Caro, Antonino
Capobianchi, Maria R.
Castilletti, Concetta
Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
title Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
title_full Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
title_fullStr Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
title_full_unstemmed Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
title_short Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
title_sort antagonistic antiviral activity between ifn-lambda and ifn-alpha against lethal crimean-congo hemorrhagic fever virus in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333211/
https://www.ncbi.nlm.nih.gov/pubmed/25693189
http://dx.doi.org/10.1371/journal.pone.0116816
work_keys_str_mv AT bordilicia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT lalleeleonora antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT caglioticlaudia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT travaglinidamiano antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT lapadaniele antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT marsellapatrizia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT quartuserena antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT kiszoltan antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT arienkevink antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT huemerhartwigp antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT meschisilvia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT ippolitogiuseppe antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT dicaroantonino antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT capobianchimariar antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro
AT castilletticoncetta antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro